Fabienne Pichon
Overview
Explore the profile of Fabienne Pichon including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
308
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Geoerger B, Morland B, Ndiaye A, Doz F, Kalifa G, Geoffray A, et al.
Eur J Cancer
. 2009 Apr;
45(13):2342-51.
PMID: 19362466
Aim: To explore imatinib efficacy and pharmacokinetics in children and adolescents with refractory/relapsing solid tumours, expressing imatinib-sensitive receptor tyrosine kinases. Methods: Exploratory study on imatinib in tumours expressing, at least,...
2.
Ridola V, Fawaz O, Aubier F, Bergeron C, De Vathaire F, Pichon F, et al.
Eur J Cancer
. 2009 Feb;
45(5):814-8.
PMID: 19216070
Purpose: This study aimed at comparing gonadal toxicity of ifosfamide versus cyclophosphamide received during childhood. Methods: The evaluation was based on basal FSH measurement. LH and testosterone were also measured...
3.
Vassal G, Giammarile F, Brooks M, Geoerger B, Couanet D, Michon J, et al.
Eur J Cancer
. 2008 Sep;
44(16):2453-60.
PMID: 18812255
Purpose: To evaluate the efficacy and safety of irinotecan in paediatric recurrent or refractory neuroblastoma. Patients And Methods: Thirty seven patients aged between 6 months and < or = 20...
4.
Geoerger B, Doz F, Gentet J, Mayer M, Landman-Parker J, Pichon F, et al.
J Clin Oncol
. 2008 Sep;
26(27):4394-400.
PMID: 18802151
Purpose: To explore feasibility, maximum-tolerated dose (MTD), and recommended dose (RD) for phase II studies of weekly oxaliplatin for the treatment of relapsed or refractory pediatric solid malignancies. Patients And...
5.
Baroncini M, Vinchon M, Mineo J, Pichon F, Francke J, Dhellemmes P
Childs Nerv Syst
. 2007 Mar;
23(7):753-60.
PMID: 17370079
Objectives: Thalamic tumors are uncommon, and although gross total removal (GTR) is a prospective goal, its interest is debated because the thalamus constitutes a highly functional region. The relation of...
6.
Le Deley M, Guinebretiere J, Gentet J, Pacquement H, Pichon F, Marec-Berard P, et al.
Eur J Cancer
. 2007 Feb;
43(4):752-61.
PMID: 17267204
The SFOP-OS94 randomised multi-centre trial was designed to determine whether preoperative chemotherapy regimen combining high-dose methotrexate courses and etoposide-ifosfamide could improve the proportion of good histologic response (5% viable cells)...
7.
Vassal G, Couanet D, Stockdale E, Geoffray A, Geoerger B, Orbach D, et al.
J Clin Oncol
. 2007 Feb;
25(4):356-61.
PMID: 17264330
Purpose: This phase II study was designed to evaluate the efficacy of irinotecan administered intravenously once every 3 weeks in pediatric patients with recurrent or refractory rhabdomyosarcoma. Patients And Methods:...
8.
Grill J, Sainte-Rose C, Jouvet A, Gentet J, Lejars O, Frappaz D, et al.
Lancet Oncol
. 2005 Aug;
6(8):573-80.
PMID: 16054568
Background: Morbidity and mortality are high in young children with medulloblastoma who receive craniospinal radiotherapy. We aimed to assess whether adjuvant treatment with protracted chemotherapy alone could replace radiotherapy. Methods:...
9.
Penel N, Depadt G, Vilain M, Vanseymortier L, Ceugnart L, Taieb S, et al.
Bull Cancer
. 2004 Jan;
90(10):887-95.
PMID: 14706917
Little is known about epidemiology of adults soft tissue and visceral sarcomas (ASTS). The frequency of previous cancers and associated genetic diseases has been analyzed out of 493 ASTS, treated...
10.
Laithier V, Grill J, Le Deley M, Ruchoux M, Couanet D, Doz F, et al.
J Clin Oncol
. 2003 Dec;
21(24):4572-8.
PMID: 14673044
Purpose: To evaluate a strategy aimed at avoiding radiotherapy during first-line treatment of children with progressive optic pathway tumors (OPT), by exclusively administering multiagent chemotherapy during 16 months. Patients And...